PL8177 / Palatin Technologies 
Welcome,         Profile    Billing    Logout  
 0 Diseases   1 Trial   1 Trial   5 News 
  • ||||||||||  PL8177 / Palatin Technologies
    Biomarker, Trial completion date, Trial primary completion date:  PL8177-205: Phase 2a To Evaluate PL-8177 in Subjects With Active Ulcerative Colitis (UC) (clinicaltrials.gov) -  Feb 9, 2023   
    P2a,  N=28, Recruiting, 
    Collectively, these findings support further research into the oral formulation of PL8177 as a possible therapeutic for GI inflammatory diseases in humans. Trial completion date: Jun 2023 --> Oct 2023 | Trial primary completion date: Mar 2023 --> Jul 2023
  • ||||||||||  PL8177 / Palatin Technologies
    Journal:  Pro-resolving and anti-arthritic properties of the MC selective agonist PL8177. (Pubmed Central) -  Dec 13, 2022   
    Using a mouse model of inflammatory arthritis, the compound demonstrated in vivo efficacy by reducing clinical score, paw swelling and overall disease severity. Taken together, these results present Melanocortin-based therapies, and specifically targeting MC receptor, as a promising strategy to manage chronic inflammatory diseases.
  • ||||||||||  PL8177 / Palatin Technologies, PL9654 / Palatin Technologies
    Efficacy and impact of the melanocortin receptor agonists PL8177 and PL9654 in an STZ-rat model of diabetic retinopathy (DR) (A0047) -  Apr 29, 2022 - Abstract #ARVO2022ARVO_1943;    
    SC BID administration of the melanocortin agonists PL9654 and PL8177 show promise in the treatment of DR by reducing vision loss and photoreceptor degeneration in the STZ-rat model of DR. Single nuclei RNAseq and proteomic data will be interpreted in the context of disease change to identify alterations in immune and cellular states of the rat retinas.
  • ||||||||||  PL8177 / Palatin Technologies, PL8331 / Palatin Technologies
    The Effects Of Melanocortin Receptor Agonists On Experimental Autoimmune Uveitis (A0521) -  Apr 29, 2022 - Abstract #ARVO2022ARVO_1243;    
    Our previous studies showed the importance of the melanocortins in the maintenance of ocular immune privilege and that α-MSH-treatment accelerated recovery and induced retinal-antigen-specific regulatory immunity. Our current results demonstrated that α-MSH-analogs targeting MC1r and MC5r together have a therapeutic potential to suppress uveitis and induce regulatory immunity.
  • ||||||||||  PL8177 / Palatin Technologies, PL8331 / Palatin Technologies
    Journal:  Melanocortin receptor agonists suppress experimental autoimmune uveitis. (Pubmed Central) -  Apr 28, 2022   
    Our current results show that this activity is centered around MC1r and MC5r. In addition, the results suggest that a therapeutic potential to target MC1r and MC5r together to suppress uveitis induces regulatory immunity with potentially maintaining a normal retinal structure.
  • ||||||||||  PL8177 / Palatin Technologies
    CELLULAR AND MOLECULAR IMPACT OF THE MELANOCORTIN RECEPTOR AGONIST PL8177 IN DEXTRAN SODIUM SULFATE (DSS)-INDUCED COLITIS IN RATS (Poster Hall - San Diego Convention Center) -  Apr 25, 2022 - Abstract #DDW2022DDW_1740;    
    Conclusion : Oral PL8177 treatment of inflamed colon showed significant improvement in markers of colitis in the rat model compared to the placebo and mesalazine control groups, supporting the aim of treating inflammatory bowel disease in humans. Genomic and proteomic data will be interpreted in the context of disease change to identify alterations in immune and cellular states of the experimental colons.
  • ||||||||||  PL8177 / Palatin Technologies
    CELLULAR AND MOLECULAR IMPACT OF THE MELANOCORTIN RECEPTOR AGONIST PL8177 IN DEXTRAN SODIUM SULFATE (DSS)-INDUCED COLITIS IN RATS () -  Jan 28, 2022 - Abstract #CCCongress2022CCCongress_206;    
    CONCLUSION Oral PL8177 treatment of inflamed colon showed significant improvement in markers of colitis in the rat model compared to the placebo and mesalazine control groups supporting the aim of treating inflammatory bowel disease in humans. Genomic and proteomic data will be interpreted in the context of disease change to identify alterations in immune and cellular states of the experimental colons.
  • ||||||||||  PL8177 / Palatin Technologies
    PK/PD data, Journal:  Pharmacokinetics of the Melanocortin Type 1 Receptor Agonist PL8177 After Subcutaneous Administration. (Pubmed Central) -  Nov 24, 2021   
    Rapid absorption was seen in healthy volunteers, and multiple-dose administration over 7 days resulted in pharmacokinetic characteristics similar to those observed after single-dose administration. Results support the continued development of PL8177 to treat immunologic and inflammatory conditions.
  • ||||||||||  PL8177 / Palatin Technologies
    [VIRTUAL] ORAL ADMINISTRATION OF THE MELANOCORTIN-1 RECEPTOR AGONIST PL8177 IN A RAT MODEL OF COLITIS (DDW Virtual) -  Mar 15, 2021 - Abstract #DDW2021DDW_3429;    
    Significant protective effects of 50 µg oral polymer-encapsulated PL8177 were observed across multiple outcomes of colon damage. Based on previously demonstrated protective effects of IC PL8177 1.5-µg and 5-µg doses, these results suggest an approximate 33-fold difference between optimal doses for IC versus oral delivery and support the continued development of PL8177 for the treatment of IBD.